Biotia's BIOTIA-DX Resistance tool achieved the highest prediction accuracy in the 2025 CAMDA Antimicrobial Resistance Challenge. Read more on Biotia →
TETmedical appointed diagnostics commercialization executive Arjun Ishwar as chief commercial officer as NSE-FAST advances toward pivotal study.
A peer-reviewed preclinical study found AVA-003 outperformed chlorhexidine against Candida auris on skin, advancing AvantGuard’s development program.
